Here’s a hint. It is the lack of investor’s confidence in ability for management team to execute and get the job done. They have submitted multiple filings and failed each one, either through lack of expertise, misunderstanding the FDA and/or both. The picture is clear as day, but Nasrat is tied at the hip to Elite so the anchor isn’t going away. Don’t get me started on the CFO...
Because as UN-elite has proven APPROVALS don't come the first time. There are way too many things to go wrong than right. Especially when dealing with the fda.